Class Action Lawsuit Filed Against aTyr Pharma Inc.
The Law Offices of Frank R. Cruz has officially announced the initiation of a class action lawsuit aimed at protecting shareholders of aTyr Pharma Inc. (NASDAQ: ATYR). This action is directed at investors who acquired shares of the company between January 16, 2025, and September 12, 2025. Shareholders are encouraged to file lead plaintiff motions by December 8, 2025, to ensure their voices are heard in this legal proceeding.
Details of the Allegations
Recent developments concerning aTyr Pharma’s clinical trials have prompted this legal action. On September 15, 2025, the company disclosed that its Phase 3 clinical trial for the treatment of pulmonary sarcoidosis using its drug, Efzofitimod (designated EFZO-FIT), failed to meet key efficacy benchmarks. Following this announcement, aTyr‘s stock price plummeted significantly, closing at just $1.02 per share after dropping by more than 83%. This sharp decline has raised concerns among investors, many of whom are now questioning the integrity of the information provided by the company.
The lawsuit contends that throughout the class period, the executives of aTyr issued misleading statements regarding the prospects of Efzofitimod. It is alleged that the company created an illusion of confidence about the drug’s success in clinical trials while concealing critical adverse details about the study’s design and expected outcomes. Specifically, the complaint suggests that there was a deliberate omission of information indicating that the Phase 3 trial might not achieve its primary endpoint, which was a significant change in mean daily oral corticosteroid (OCS) dosage after 48 weeks.
Moreover, the suit claims that the defendants promoted a narrative that misled investors into believing that the EFZO-FIT study would facilitate complete steroid cessation in treatment plans. However, the failure to meet the primary endpoint has resulted in a misleading portrayal of the company’s operational health and future prospects.
How to Get Involved
Investors who purchased shares in aTyr Pharma and wish to learn more about the class action or have inquiries regarding their rights in relation to this situation are encouraged to reach out. Interested parties can contact the Law Offices of Frank R. Cruz via email at info@frankcruzlaw.com or by phone at (310) 914-5007. Additional information can also be found on their website at www.frankcruzlaw.com.
This announcement is categorized as Attorney Advertising in certain jurisdictions and aims to inform affected shareholders of their potential rights and options following this significant market event. Investors are urged to act quickly to ensure their claims are secured in the ongoing litigation regarding aTyr Pharma Inc..
Related
